One of the largest phase 3 trials of adjuvant bisphosphonate therapy in women with breast cancer has shown that zoledronic acid does not improve overall survival or prevent cancer recurrence. Almost universally, experts called the findings a disappointment. But the study, known as AZURE, has generated a new hypothesis: adjuvant therapy with the bone-building drug may improve survival odds and reduce the risk of disease progression in women with low estrogen levels from natural menopause or medication-induced ovarian suppression.
Voelker R. “Disappointing” Trial Results Offer Hope for Older Women With Breast Cancer. JAMA. 2011;305(8):765-766. doi:10.1001/jama.2011.172